Trial by fire: Two Cambridge biotechs race to find a gene therapy cure for Duchenne – Boston Business Journal
Boston Business Journal |
Trial by fire: Two Cambridge biotechs race to find a gene therapy cure for Duchenne
Boston Business Journal It was the kind of moment most biotechs only dream about: In September 2016, the FDA approved Sarepta Therapeutics' first drug, a treatment for Duchenne muscular dystrophy. Previously, there had been no approved drugs for the deadly genetic disease … |
